|
DENVER, Dec. 16 /PRNewswire-FirstCall/ -- Myogen, Inc.
(Nasdaq: MYOG) announced today that Judith A. Hemberger, Ph.D. has been
appointed to the Companys Board of Directors. Dr. Hemberger is Executive
Vice President and Chief Operating Officer of Pharmion Corporation.
"We are extremely pleased that Dr. Hemberger has agreed to join the Myogen
Board of Directors," stated J. William Freytag, President and CEO of Myogen.
"Dr. Hemberger brings over 25 years experience in global regulatory and
medical affairs in the pharmaceutical industry to help guide Myogens future
growth. We believe she will be a great asset to the Companys Board and its
stockholders."
Prior to co-founding Pharmion, Dr. Hemberger worked as a consultant to
various healthcare companies. During this period, she also served as a Senior
Vice President of Business Development at AVAX Technologies, Inc., a vaccine
technology company. From 1979 through 1997, Dr. Hemberger worked at Marion
Laboratories and successor companies Marion Merrell Dow and Hoechst Marion
Roussel. She led a number of strategic functions, including Professional
Education, Global Regulatory Affairs, Global Medical Affairs, and Commercial
Development. Her final role in the company was Senior Vice President of
Global Drug Regulatory Affairs. Dr. Hemberger currently serves on the Board
of Directors of Pharmion Corporation, PRA International, Perrigo Company and
Renovis, Inc.
About Myogen
Myogen is a biopharmaceutical company focused on the discovery,
development and commercialization of small molecule therapeutics for the
treatment of cardiovascular disorders. Myogen currently has two product
candidates in late-stage clinical development: ambrisentan for the treatment
of patients with pulmonary arterial hypertension (PAH) and darusentan for the
treatment of patients with resistant hypertension. The Company, in
conjunction with Novartis, also conducts a target and drug discovery research
program focused on the development of disease-modifying drugs for the
treatment of chronic heart failure and related cardiovascular disorders.
Please visit our website at http://www.myogen.com.
Safe Harbor Statement
This press release contains forward-looking statements that involve
significant risks and uncertainties, including summary statements relating to
Myogens future growth. Actual results could differ materially from those
projected and the Company cautions investors not to place undue reliance on
the forward-looking statements contained in this release.
Additional risks and uncertainties relating to the Company and its
business can be found in the "Risk Factors" section of Myogens Form 10-K for
the year ended December 31, 2004 and Myogens reports on Form 10-Q and Form
8-K. It is Myogens policy to only update or reconfirm its public guidance
by issuing a press release or filing a periodic or current report with the
Securities and Exchange Commission. The Company generally plans to provide
guidance as part of its annual and quarterly earnings releases but reserves
the right to provide guidance at different intervals or to revise its practice
in future periods. All information in this press release is as of
December 16, 2005. Myogen undertakes no duty or obligation to update any
forward-looking statements contained in this release as a result of new
information, future events or changes in the Companys expectations. The
Company also disclaims any duty to comment upon or correct information that
may be contained in reports published by the investment community.
|
|
